Bristol Myers Squibb brought in more than $9 billion in sales from its anticoagulant Eliquis in 2020, and it continues to see growth with more than $8 billion in sales in the first nine months of 2021 (and another nearly $4.5 billion for Pfizer in 2021).
But in 2022, one of the largest PBMs in the US, CVS Caremark, has recently decided to no longer cover the megablockbuster, and instead will only offer coverage for warfarin and Janssen’s Xarelto.
https://endpts.com/cvs-takes-a-swing-at-bristol-myers-and-pfizer-excluding-coverage-of-their-megablockbuster-eliquis-in-2022
